It is very important to remember - Kevetrin is NON-geno toxic . This drug does not harm surrounding healthy DNA
Most cancer treatments in trials today fail because of high toxicity, and this is part of what makes Kevetrin such a compelling treatment, the non-geno toxic nature of the drug
Today’s cancer treatments are still a figurative “bull in a china shop”. They come into your body, and attack cancers aggressively, however they also attack the host as well
Kevetrin works by re-building your body’s cancer “attack dog”, without harming surrounding DNA, a much more humane and advanced way of attacking the disease and not the patient
The man behind the drug, Dr Krishna Menon, is a world renowned cancer researcher who has already helped successfully bring to market multiple other billion dollar cancer drugs (Gemzar and Alimta – both multi-billion dollar drugs)
Kevetrin is set to start its already paid for phase 1 clinical trials at Harvard's Dana Farber Cancer Institute, IMO the world's premiere cancer research and treatment facility – this phase 1 trial is set to start on or around 11/1/12
Normal phase 1 trials test on healthy volunteers and test primarily for safety. Cancer trial drugs are often given to Stage 4 terminally ill patients who usually have cancers that are already resistant to all existing therapies. Since these are the patients Cellceutix is anxious to treat, positive results could springboard development to fast-track status
The way that Dana Farber has laid out the clinical trial for Kevetrin is brilliant in the respect that it offers the FDA the exact and specific data points that will make it easier fro them to justify designating Kevetrin as a “breakthrough technology” therefore accelerating trials even beyond normal “fast tracking” status
Kevetrin will also concurrently be running an already paid for combined phase 1 trial with some of Pfizer's premiere cancer drugs – as CTIX has already signed a non-disclosure agreement with Pfizer
Cellceutix is also in negotiations with one of Europe's most distinguished Leukemia research schools, for a trial that will also be paid for by the University, saving Cellceutix millions in trial costs
Also, the value of the strong Kevetrin patent (written by Dr Paul Ginsberg, the man who wrote the Claritin patent) literally covers tens of thousands of possible future chemical combinations for new drugs; a potentially very valuable proposition for multiple drug development
The CEO understands very well the potential value of Kevetrin, and has openly stated that he will not be interested in a buy out until Kevetrin has been advanced through trials far enough to generate maximum buyout value and shareholder ROI
Bottom Line : Kevetrin has the potential to become the standard next generation broad spectrum cancer treatment, and in doing so can provide transformational profits to investors that invest in the company before any further major developments
